Section Arrow
REPL.NASDAQ
- Replimune Group
Quotes are at least 15-min delayed:2026/07/11 11:05 EDT
Regular Hours
Last
 10.99
-0.12 (-1.08%)
Day High 
11.11 
Prev. Close
11.11 
1-M High
12.5 
Volume 
2.30M 
Bid
11
Ask
11.09
Day Low
10.46 
Open
11.1 
1-M Low
8.25 
Market Cap 
932.63M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 11.3 
20-SMA 10.54 
50-SMA 7.48 
52-W High 13.24 
52-W Low 1.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.38/-2.71
Enterprise Value
1.04B
Balance Sheet
Book Value Per Share
1.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABPmgc Holdings Inc1.12+0.06+5.66%-- 
RXRXRecursion Pharmaceuticals3.56-0.2-5.32%-- 
VYNEVYNE Therapeutics0.6376-0.0344-5.12%-- 
HUMAHumacyte0.6937-0.0066-0.94%-- 
GOSSGossamer Bio0.1697-0.0053-3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.